ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
78 hedge funds and large institutions have $116M invested in Adaptimmune Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
33% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 24
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
Holders
78
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$2.46M | |
| 2 | +$1.61M | |
| 3 | +$374K | |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$218K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$140K |
Top Sellers
| 1 | -$397K | |
| 2 | -$373K | |
| 3 | -$329K | |
| 4 |
Millennium Management
New York
|
-$274K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$254K |